This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Archives of Physical Medicine and Rehabilitation 95:1141-7 (2014)
Authors: R Chieffo, S De Prezzo, E Houdayer, A Nuara, G Di Maggio, E Coppi, L Ferrari, L Straffi, F Spangnolo, S Velikova, M Sessa, M Comola, A Zangen, G Comi, L Leocani
Chieffo, R., De Prezzo, S., Houdayer, E., Nuara, A., Di Maggio, G., Coppi, E., & Leocani, L. (2014). Archives of physical medicine and rehabilitation.
This study examined the effect of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) on patients that suffer from stroke-induced impairment of the lower limb motor function. There were two treatment periods, each comprising 11 sessions over 3 weeks, and separated by a 4-week period. The study showed that Deep TMS could generate long-term improvements in the functioning of the lower limb. In this study it was demonstrated that Brainsway Deep Transcranial Magnetic Stimulation results in significant and long lasting alleviation of symptoms.